Sedation Regimens for Gastrointestinal Endoscopy

Sung-Hoon Moon

doi:10.5946/ce.2014.47.2.135

Articles

Page Path: HOME > Clin Endosc > Volume 47(2); 2014 > Article

Focused Review Series: Endoscopic Sedation Revisited: Principles and Practice Sedation Regimens for Gastrointestinal Endoscopy: Sung-Hoon Moon; Clinical Endoscopy 2014;47(2):135-140.
DOI: https://doi.org/10.5946/ce.2014.47.2.135
Published online: March 31, 2014

Department of Internal Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea.

Correspondence: Sung-Hoon Moon. Department of Internal Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, 22 Gwanpyeong-ro 170beon-gil, Dongan-gu, Anyang 431-796, Korea. Tel: +82-31-380-3710, Fax: +82-31-386-2269, endomoon@naver.com

• Received: January 21, 2014 • Accepted: February 26, 2014

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

13,360 Views
285 Download
45 Web of Science
47 Crossref
44 Scopus

prev next

Full Article

Download PDF

Abstract
INTRODUCTION
SEDATION AND ANALGESIA FOR GASTROINTESTINAL ENDOSCOPY
PHARMACOLOGY OF SEDATIVES AND ANALGESICS
SEDATION REGIMENS FOR ENDOSCOPISTS IN ACTUAL PRACTICE
CONCLUSIONS
NOTES
REFERENCES

Abstract

Sedation allows patients to tolerate unpleasant endoscopic procedures by relieving anxiety, discomfort, or pain. It also reduces a patient's risk of physical injury during endoscopic procedures, while providing the endoscopist with an adequate setting for a detailed examination. Sedation is therefore considered by many endoscopists to be an essential component of gastrointestinal endoscopy. Endoscopic sedation by nonanesthesiologists is a worldwide practice and has been proven effective and safe. Moderate sedation/analgesia is generally accepted as an appropriate target for sedation by nonanesthesiologists. This focused review describes the general principles of endoscopic sedation, the detailed pharmacology of sedatives and analgesics (focused on midazolam, propofol, meperidine, and fentanyl), and the multiple regimens available for use in actual practice.
Keywords: Sedation; Endoscopy; Analgesia; Endoscopic sedation

INTRODUCTION

Sedation, which can be defined as a drug-induced depression in the level of consciousness, is regarded by many endoscopists as an essential component of gastrointestinal endoscopy.1 Endoscopic procedures such as esophagogastroduod-enoscopy (EGD) and colonoscopy can be performed without sedation in some patients with certain characteristics, but these procedures are better tolerated when adequate sedation is administered. This is especially the case for more complex endoscopic procedures such as endoscopic retrograde cholangiopancreatography.2 Sedation allows patients to tolerate unpleasant procedures by relieving anxiety, discomfort, or pain, and it also reduces a patient's risk of physical injury during endoscopic procedures while providing the endoscopist with an adequate setting for a detailed examination.1

Expertise in the pharmacology, physiology, and clinical management of patients receiving sedation and analgesia is therefore very relevant to endoscopists.3 Endoscopic sedation by nonanesthesiologists is a worldwide practice that has been confirmed as effective and safe, especially when targeted to moderate sedation/analgesia.4,5,6,7,8 Propofol, as well as traditional agents (benzodiazepines and/or narcotics), can be safely titrated by endoscopists to provide adequate sedation.7 This focused review describes the basics of sedation, the pharmacology of sedatives and analgesics, and the multiple regimens available for use in actual practice.

SEDATION AND ANALGESIA FOR GASTROINTESTINAL ENDOSCOPY

The aim of endoscopic sedation is to reduce patient discomfort, including anxiety and pain, while preserving a minimum rate of drug-related adverse events.1 Sedative drugs produce hypnosis and amnesia of discomfort but no analgesia, while opioid narcotics produce potent analgesia but little sedation.9 If analgesics are properly used, the amount of sedative required for satisfactory endoscopic sedation can be substantially reduced. Endoscopists should consider both patient and procedural factors for adequate and safe sedation. Patient factors include age, body mass, medical history, concurrent medications, preprocedural anxiety, previous responses to sedation, and pain tolerance.1,6,10 Procedural factors include the level of procedure-related discomfort, the need for the patient to lie relatively motionless, and the duration of examination.1,6,10 Optimal sedation by endoscopists is indicated in the sedation training curriculum for gastrointestinal endoscopy published by the gastroenterology and endoscopy societies, which includes concepts of sedation, preprocedural assessment, sedation pharmacology, patient monitoring, training in airway/rescue techniques, management of complications, and so forth.6,11 Table 1 summarizes the general principles of endoscopic sedation for nonanesthesiologists.3,6,8,9

PHARMACOLOGY OF SEDATIVES AND ANALGESICS

Endoscopists must understand the pharmacology, pharmacokinetics (time of onset, peak response, and duration of effect), pharmacodynamics, adverse effects, and drug-drug interactions of any sedative and analgesic that they use (Table 2). The most common agents used for endoscopic sedation are benzodiazepines (more specifically midazolam), opioids, and propofol.

Midazolam

Benzodiazepines have multiple pharmacologic effects that help facilitate sedation for endoscopy through interactions with the γ-aminobutyric acid (GABA) receptor. When benzodiazepines bind to the type A GABA (GABA_A) receptor within the cerebrum and cerebellar cortex, they increase the binding affinity for GABA (inhibitory neurotransmitter) and promote its inhibitory action on the central nervous system.1,12 As a result, benzodiazepines have anxiolytic, euphoriant, sedative-hypnotic, amnestic (anterograde), anticonvulsant, and muscle-relaxing effects. The commonly used benzodiazepines for endoscopic sedation have been midazolam and diazepam, but midazolam is the benzodiazepine of choice due to the shorter duration of its effect and its better pharmacokinetic profile compared to diazepam.4,8,12 In addition, midazolam is 1.5 to 3.5 times more potent than diazepam.1

Midazolam is a water soluble benzodiazepine that is available parenterally and shows a pH-dependent solubility. In an acidic solution (pH <3-4), midazolam is water-soluble. After intravenous administration, midazolam undergoes an intramolecular reconfiguration at physiological pH (7.4) to yield the classic lipophilic benzodiazepine structure.1,12 The high lipophilicity of midazolam results in its rapid distribution across the blood-brain barrier to its site of action, i.e., the central nervous system. Midazolam is metabolized in the liver through oxidative and conjugative metabolism, and its metabolites are excreted by the kidney.

The onset of effect for midazolam is 1 to 2.5 minutes, the peak effect is at 3 to 4 minutes, and the duration of effect is 15 to 80 minutes. The duration of the effect of midazolam depends on the duration of its administration.4 Midazolam clearance is reduced in the elderly, the obese, and those with hepatic or renal impairment.1 The major adverse effects are respiratory depression, apnea, and hypotension. The respiratory depressant effect of benzodiazepines is dose dependent and results from depression of the central ventilator response to hypoxia and hypercapnia. Paradoxical reactions, including hyperactive or aggressive behavior, have been reported with benzodiazepines.4 The administration of flumazenil (a benzodiazepine antagonist) can reverse sedation, psychomotor impairment, memory loss, and respiratory depression.6 The onset of action for flumazenil is 1 to 2 minutes and the duration of its effect is 60 minutes.

Propofol

Propofol (2,6-diisopropofol) is a sedative-hypnotic drug with an amnestic effect, but a minimal analgesic effect. Its hypnotic effect results from potentiating GABA through the GABA_A receptor in a manner similar to that of benzodiazepines.12 The depth of sedation increases in a dose-dependent manner. Serum levels of propofol should be greater than 1 µg/mL to produce sleep.12 The current formulation of propofol contains 1% propofol (10 mg/mL), 10% soybean oil, 2.25% glycerol, and 1.2% purified egg phosphatide. Propofol has the benefits of a very rapid onset of action and a short recovery time.

Propofol is highly lipophilic and rapidly crosses the blood-brain barrier. It is metabolized rapidly in the liver via hydroxylation and conjugation with glucuronide and sulfate, and its metabolites are excreted by the kidney. The onset of effect for propofol is 0.5 to 1 minutes and the duration of effect is 4 to 8 minutes. The pharmacokinetic parameters of propofol vary with patient factors such as weight, sex, age, and concomitant disease. Because elderly patients have a decreased volume of distribution and total body clearance for propofol, they are more sensitive to propofol.12 Chronic kidney disease or liver cirrhosis does not significantly alter propofol pharmacokinetics.1,12

Major adverse effects are respiratory depression, hypotension, and pain on injection.1 Hypotension results from the cardiovascular effects of propofol including decreased cardiac output and systemic vascular resistance. With overdosing, respiratory depression generally precedes clinically significant hypotension.8 Pain on injection is reported by up to 30% of patients, especially when receiving an intravenous bolus of propofol. That there is no existing pharmacologic antagonist is a disadvantage of propofol, although hypotension and respiratory depression typically responds rapidly to a dose reduction or interruption of drug infusion.

Opioids

The opioid class of drugs has potent analgesic with some sedative effects. Opioid analgesics mainly inhibit neurotransmission of pain by binding to specific opioid receptors that are present in the central nervous system and peripheral tissues. Properties of opioid analgesics include rapid onset, ease of titration, and no ceiling effect. Among the opioid analgesics (morphine, meperidine, fentanyl, remifentanil, and so forth), meperidine and fentanyl are the most commonly used for endoscopic sedation. The equianalgesic dose refers to the relative potency of two opioids to produce the same analgesic effect.12 The standard comparison dose is 10 mg parenteral morphine, which is equivalent to 75 mg of meperidine and 0.1 mg of fentanyl.

Meperidine is a full opioid agonist with effects similar to those of morphine. The onset of action for meperidine is 3 to 6 minutes when intravenously administered and 10 to 15 minutes when administered intramuscularly.1,12 The duration of effect is 60 to 180 minutes. Meperidine is metabolized in the liver and excreted in the urine. All opioids increase biliary tract pressure, but meperidine has a lesser effect.12

Fentanyl, a synthetic full opioid agonist, is highly lipid-soluble and 80 to 100 times as potent as morphine. The onset of action for fentanyl is 1 to 2 minutes and its duration of effect is 30 to 60 minutes. Fentanyl is metabolized in the liver and excreted in the urine.

Common adverse effects of opioids include constipation, respiratory depression, miosis, nausea and vomiting, urinary retention, and myoclonus.12 Respiratory depression occurs in a dose-dependent manner, and the concomitant use of a benzodiazepine with an opioid has a synergistic effect on the risk of respiratory depression. Opioid analgesics usually produce only mild hemodynamic depression.12 Among the opioids, fentanyl has relatively little effect on the cardiovascular system.1 Nausea and vomiting resulting from stimulation of the medullary chemoreceptor trigger zone occurs in a dose-independent manner.1 Naxloxone is a pure antagonist for opioid receptors and is used to reverse the effects of the opioid narcotics. The onset of action for naloxone is 1 to 2 minutes and the duration of its effect is 30 to 45 minutes.

SEDATION REGIMENS FOR ENDOSCOPISTS IN ACTUAL PRACTICE

Implementation of an evidence-based sedation regimen may improve the quality of sedation practice and reduce the incidence of sedation-related adverse events.1 However, a fine line may exist between over- and under-sedation in actual practice.12 Experience combined with knowledge is required for safe and effective administration of sedatives/analgesics for the purpose of induction and maintenance of moderate sedation. Table 3 describes the detailed sedation regimens for endoscopists. When deep sedation or general anesthesia is required for extended periods in complex endoscopic procedures, anesthesiologist-assisted sedation may play an important role.13

Midazolam alone

The choice of traditional sedatives/analgesics generally consists of a benzodiazepine used either alone or in combination with an opiate.10 Midazolam is the most widely used benzodiazepine drug because it has a more rapid onset of action and a shorter duration than the other benzodiazepines. The initial intravenous dose for endoscopic sedation in healthy adults younger than 60 years of age is 1 to 2 mg (or no more than 0.03 mg/kg body weight) injected over 1 to 2 minutes.1,6 Additional doses of 1 mg (or 0.02 to 0.03 mg/kg) may be administered at 2-minute intervals until adequate sedation is achieved. The usual total dose is 2.5 to 5 mg.14 A maximal dosage of midazolam for routine endoscopic procedure is 6 to 7.5 mg.6,15 A reduction in the midazolam dosage (20% or more) is required for patients older than 60 years of age and for those with American Society of Anesthesiologists physical status III or greater.

Midazolam plus opioids

When midazolam is used in combination with an opioid analgesic, a reduction in the dosage of midazolam/opioids may be indicated due to a synergistic interaction.1 The initial doses are 0.5 to 1 mg midazolam plus 12.5 to 50 mg meperidine or 12.5 to 75 µg fentanyl.16,17,18,19 Additional medication is titrated at 1 to 3 minutes intervals to achieve or maintain the desired level of sedation. The time of titration can be decreased by using an initial dose of 2.5 mg midazolam and 25 to 50 mg meperidine with an additional dose of midazolam.15

Propofol alone

The clinical advantages of propofol include rapid onset and off-set of sedation with quick recovery times. A meta-analysis showed that propofol allows a more rapid initiation of sedation (2 vs. 6 to 8.5 minutes) and a shorter recovery time (15 vs. 50 to 55 minutes) when compared with midazolam-based regimens.20 Many patients who receive propofol alone may require deep sedation because propofol provides no analgesic effect.1

The published protocols for propofol recommend an initial bolus of propofol ranging from 10 to 60 mg, followed by additional boluses of 10 to 20 mg administered with a minimum of 20 to 30 seconds between doses.1 The short duration of action of propofol may require frequent and somewhat technically demanding propofol administration to maintain sedation levels.

Continuous infusion of propofol by pumps may theoretically be associated with a reduced need for nurse intervention and a more stable maintenance of a consistent level of sedation. The published protocols for continuous propofol infusion states are 2 to 5 mg/kg/hr (or 100 to 200 mg/hr), sometimes with an initial 0.25 to 0.5 mg/kg bolus.9,21,22,23 Although continuous infusion of propofol by a pump is widely used in anesthesia practice and the pumps are easily programmed, most nonanesthesiologists prefer the flexibility of the bolus approach.9,21

Balanced propofol sedation (combination propofol)

Balanced propofol sedation is analogous to balanced anesthesia, which is a well-established pharmacologic concept in the practice of general anesthesia. Balanced anesthesia involves the administration of a mixture of small amounts of several neuronal depressants to maximize the therapeutic actions while minimizing the likelihood of a dose-related adverse reaction from any of the individual drugs.1 In endoscopic practice, balanced propofol sedation describes the use of an opioid and/or benzodiazepine, where each is given as a single dose, followed by small incremental doses of propofol administered to achieve a target level of sedation (preferably moderate sedation).5,6 Balanced propofol sedation can provide the benefits of propofol-mediated sedation while reducing the risk of rapid, irreversible oversedation.1 However, recovery time from balanced propofol sedation might be longer than recovery from propofol only.

The published protocols for balanced propofol sedation dictate a pre-induction dose of either an opioid (fentanyl, 25 to 75 µg; meperidine, 25 to 50 mg), midazolam (0.5 to 2.5 mg), or both.1,24,25 An initial bolus of propofol (10 to 40 mg, or up to 0.5 mg/kg) is then administered, followed by additional boluses of 5 to 20 mg titrated to achieve the target level of sedation.6,24,25 Maintenance of sedation is achieved with repeated doses of 5 to 20 mg propofol. The average cumulative doses of propofol in balanced propofol sedation are 65 to 100 mg for colonoscopy and 35 to 70 mg during EGD.1

CONCLUSIONS

Various sedation regimens using a single agent or mixture of sedatives and analgesics are now used for gastrointestinal endoscopy. Because endoscopic sedation by nonanesthesiologists is a worldwide practice, it is important for endoscopists to be fully aware of the general principles of sedation and the pharmacology of any sedative and analgesic that they use. Experience combined with knowledge will promote optimal administration of sedatives/analgesics for the purpose of induction and maintenance of moderate sedation. Sedation regimens for adequate and safe sedation continue to evolve.

The author has no financial conflicts of interest.

REFERENCES

1. Cohen LB, Delegge MH, Aisenberg J, et al. AGA Institute review of endoscopic sedation. Gastroenterology 2007;133:675–701.Article PubMed
2. Dumonceau JM, Riphaus A, Aparicio JR, et al. European Society of Gastrointestinal Endoscopy, European Society of Gastroenterology and Endoscopy Nurses and Associates, and the European Society of Anaesthesiology Guideline: non-anesthesiologist administration of propofol for GI endoscopy. Endoscopy 2010;42:960–974.Article PubMed
3. American Society of Anesthesiologists Task Force on Sedation and Analgesia by Non-Anesthesiologists. Practice guidelines for sedation and analgesia by non-anesthesiologists. Anesthesiology 2002;96:1004–1017.Article PubMed PDF
4. Triantafillidis JK, Merikas E, Nikolakis D, Papalois AE. Sedation in gastrointestinal endoscopy: current issues. World J Gastroenterol 2013;19:463–481.Article PubMed PMC
5. Vargo JJ, Cohen LB, Rex DK, Kwo PY. Position statement: nonanesthesiologist administration of propofol for GI endoscopy. Gastrointest Endosc 2009;70:1053–1059.Article PubMed
6. American Association for Study of Liver Diseases. American College of Gastroenterology. American Gastroenterological Association Institute. . Multisociety sedation curriculum for gastrointestinal endoscopy. Gastrointest Endosc 2012;76:e1–e25.Article PubMed
7. Rex DK, Deenadayalu VP, Eid E, et al. Endoscopist-directed administration of propofol: a worldwide safety experience. Gastroenterology 2009;137:1229–1237.Article PubMed
8. Rex DK. Review article: moderate sedation for endoscopy: sedation regimens for non-anaesthesiologists. Aliment Pharmacol Ther 2006;24:163–171.Article PubMed
9. Karan SB, Bailey PL. Update and review of moderate and deep sedation. Gastrointest Endosc Clin N Am 2004;14:289–312.Article PubMed
10. Standards of Practice Committee of the American Society for Gastrointestinal Endoscopy. Lichtenstein DR, Jagannath S, et al. Sedation and anesthesia in GI endoscopy. Gastrointest Endosc 2008;68:815–826.Article PubMed
11. Dumonceau JM, Riphaus A, Beilenhoff U, et al. European curriculum for sedation training in gastrointestinal endoscopy: position statement of the European Society of Gastrointestinal Endoscopy (ESGE) and European Society of Gastroenterology and Endoscopy Nurses and Associates (ESGENA). Endoscopy 2013;45:496–504.Article PubMed PDF
12. Horn E, Nesbit SA. Pharmacology and pharmacokinetics of sedatives and analgesics. Gastrointest Endosc Clin N Am 2004;14:247–268.Article PubMed
13. Vargo JJ. Anesthesia-mediated sedation for advanced endoscopic procedures and cardiopulmonary complications: of mountains and molehills. Clin Gastroenterol Hepatol 2010;8:103–104.Article PubMed
14. Waring JP, Baron TH, Hirota WK, et al. Guidelines for conscious sedation and monitoring during gastrointestinal endoscopy. Gastrointest Endosc 2003;58:317–322.Article PubMed
15. Riphaus A, Gstettenbauer T, Frenz MB, Wehrmann T. Quality of psychomotor recovery after propofol sedation for routine endoscopy: a randomized and controlled study. Endoscopy 2006;38:677–683.Article PubMed PDF
16. Laluna L, Allen ML, Dimarino AJ Jr. The comparison of midazolam and topical lidocaine spray versus the combination of midazolam, meperidine, and topical lidocaine spray to sedate patients for upper endoscopy. Gastrointest Endosc 2001;53:289–293.Article PubMed
17. Zakko SF, Seifert HA, Gross JB. A comparison of midazolam and diazepam for conscious sedation during colonoscopy in a prospective double-blind study. Gastrointest Endosc 1999;49:684–689.Article PubMed
18. Sipe BW, Rex DK, Latinovich D, et al. Propofol versus midazolam/meperidine for outpatient colonoscopy: administration by nurses supervised by endoscopists. Gastrointest Endosc 2002;55:815–825.Article PubMed
19. Ulmer BJ, Hansen JJ, Overley CA, et al. Propofol versus midazolam/fentanyl for outpatient colonoscopy: administration by nurses supervised by endoscopists. Clin Gastroenterol Hepatol 2003;1:425–432.Article PubMed
20. McQuaid KR, Laine L. A systematic review and meta-analysis of randomized, controlled trials of moderate sedation for routine endoscopic procedures. Gastrointest Endosc 2008;67:910–923.Article PubMed
21. Byrne MF, Chiba N, Singh H, Sadowski DC. Clinical Affairs Committee of the Canadian Association of Gastroenterology. Propofol use for sedation during endoscopy in adults: a Canadian Association of Gastroenterology position statement. Can J Gastroenterol 2008;22:457–459.Article PubMed PMC PDF
22. Chun SY, Kim KO, Park DS, et al. Safety and efficacy of deep sedation with propofol alone or combined with midazolam administrated by nonanesthesiologist for gastric endoscopic submucosal dissection. Gut Liver 2012;6:464–470.Article PubMed PMC
23. Riphaus A, Geist C, Schrader K, Martchenko K, Wehrmann T. Intermittent manually controlled versus continuous infusion of propofol for deep sedation during interventional endoscopy: a prospective randomized trial. Scand J Gastroenterol 2012;47:1078–1085.Article PubMed
24. Lee CK, Lee SH, Chung IK, et al. Balanced propofol sedation for therapeutic GI endoscopic procedures: a prospective, randomized study. Gastrointest Endosc 2011;73:206–214.Article PubMed
25. Lee TH, Lee CK, Park SH, et al. Balanced propofol sedation versus propofol monosedation in therapeutic pancreaticobiliary endoscopic procedures. Dig Dis Sci 2012;57:2113–2121.Article PubMed

Table 1

Clinical Pearls for Adequate and Safe Endoscopic Sedation

Table 2

Pharmacological Properties of Sedatives/Analgesics for Gastrointestinal Endoscopy

IV, intravenous.

^a)The duration of drug effect may depend on the duration of administration.

Table 3

Practical Sedation Regimens for Gastrointestinal Endoscopy

^a)Minimal interval of administration.

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

A New Method for Comprehensive Analysis of Benzodiazepine, Opioid, and Propofol Interactions and Dose Selection Rationales in Gastrointestinal Endoscopy Sedation
Jing-Yang Liou, Hsin-Yi Wang, I-Ting Kuo, Mei-Yung Tsou, Weng-Kuei Chang, Chien-Kun Ting
Anesthesia & Analgesia.2025; 140(5): 1168. CrossRef
Efficacy and Safety of Remimazolam in Short Endoscopic Procedures: A Systematic Review and Meta-Analysis
Yueyang Xin, Pei Lu, Shaodi Guan, Shaomeng Si, Rao Sun, Wei Xia, Hui Xu
Medicina.2025; 61(3): 453. CrossRef
The 50% effective dose of remimazolam combined with different doses of esketamine for painless gastroscopy
Li Zhao, Xuelei Zhou, Linlin Chen, Wei Mao, Yiping Guo, Xianchun Liu, Longyi Zhang, Ying Xie, Linji Li
Scientific Reports.2025;[Epub] CrossRef
Baseline Cannabinoid Use Is Associated with Increased Sedation Requirements for Outpatient Endoscopy
Yasmin Nasser, Soliman Biala, Millie Chau, Arun C.R. Partridge, Jeong Yun Yang, B. Cord Lethebe, Laura M. Stinton, Mohan Cooray, Martin J. Cole, Christopher Ma, Yen-I Chen, Christopher N. Andrews, Nauzer Forbes
Cannabis and Cannabinoid Research.2024; 9(1): 310. CrossRef
Remimazolam for sedation in gastrointestinal endoscopy: A comprehensive review
Dushyant Singh Dahiya, Ganesh Kumar, Syeda Parsa, Manesh Kumar Gangwani, Hassam Ali, Amir Humza Sohail, Saqr Alsakarneh, Umar Hayat, Sheza Malik, Yash R Shah, Bhanu Siva Mohan Pinnam, Sahib Singh, Islam Mohamed, Adishwar Rao, Saurabh Chandan, Mohammad Al-
World Journal of Gastrointestinal Endoscopy.2024; 16(7): 385. CrossRef
Development of a predictive model for hypoxia due to sedatives in gastrointestinal endoscopy: a prospective clinical study in Korea
Jung Wan Choe, Jong Jin Hyun, Seong-Jin Son, Seung-Hak Lee
Clinical Endoscopy.2024; 57(4): 476. CrossRef
The effect of intrathecal pethidine on post-spinal anesthesia shivering after cesarean section: a systematic review and meta-analysis
Muhammad Afzal, Amber Lee, Muhammad Asad, Alya Ali, Ameer Mustafa Farrukh, Bader Semakieh, Yaxel Levin-Carrion, Shah Rukh Shah, Qaisar Ali Khan
Annals of Medicine & Surgery.2024; 86(9): 5461. CrossRef
Effect of different doses of dexmedetomidine on the median effective concentration of propofol during gastrointestinal endoscopy: a randomized controlled trial
Hai‐yan Chen, Fang Deng, Shu‐heng Tang, Wen Liu, Hua Yang, Jin‐Chao Song
British Journal of Clinical Pharmacology.2023; 89(6): 1799. CrossRef
Reconstruction of the phreno-esophageal ligament (R-PEL) prevents the intrathoracic migration (ITM) after concomitant sleeve gastrectomy and hiatal hernia repair
I. Hutopila, M. Ciocoiu, L. Paunescu, C. Copaescu
Surgical Endoscopy.2023; 37(5): 3747. CrossRef
Efficacy and safety of propofol target-controlled infusion combined with butorphanol for sedated colonoscopy
Feng Guo, De-Feng Sun, Yan Feng, Lin Yang, Jing-Lin Li, Zhong-Liang Sun
World Journal of Clinical Cases.2023; 11(3): 610. CrossRef
Technique, sedation, and clinical outcome of endoscopic submucosal dissection for rectal tumor with involvement of dentate line: A retrospective cohort study
Yoon Kyoo Noh, Jun Lee, Seong Jung Kim
Saudi Journal of Gastroenterology.2023; 29(6): 365. CrossRef
Pilot Study: Personalized Medicine in Endoscopy, Can Pharmacogenomics Predict Response to Conscious Sedation?
Himesh B. Zaver, Hassan Ghoz, Balkishan Malviya, Aman Bali, Samuel Antwi, Ann M. Moyer, Yan Bi
Journal of Personalized Medicine.2023; 13(7): 1107. CrossRef
Comparison of 95% effective dose of remimazolam besylate and propofol for gastroscopy sedation on older patients: A single‐centre randomized controlled trial
Enci Ye, Keyang Wu, Hui Ye, Wenyuan Zhang, Lihua Chu, Kai Zhang, Guohao Xie, Yue Jin, Xiangming Fang
British Journal of Clinical Pharmacology.2023; 89(11): 3401. CrossRef
Determining the 90% Effective Dose of Remimazolam Inhibiting Responses to Upper Gastrointestinal Endoscopy Insertion in Adults: A Double-Blind Study Utilizing a Biased Coin Up-and-Down Sequential Method
Pengfei Yin, Xian Zhao, Chaoliang Zhang, Yi Shi, Weiwei Sheng, Binwei Hu, Hui Li, Mi Wang, Xianhui Kang, Nizar Tlili
Journal of Clinical Pharmacy and Therapeutics.2023; 2023: 1. CrossRef
Midazolam for conscious sedation in transcatheter device closure of atrial septal defects guided solely by transthoracic echocardiography
Zeng-Chun Wang, Jian-Feng Liu, Yu-Qing Lei, Ning Xu, Shu-Ting Huang, Liang-Wan Chen, Hua Cao, Qiang Chen
Cardiology in the Young.2022; 32(2): 282. CrossRef
The median effective concentration of propofol with different doses of esketamine during gastrointestinal endoscopy in elderly patients: A randomized controlled trial
Hua Yang, Qian Zhao, Hai‐yan Chen, Wen Liu, Tong Ding, Bin Yang, Jin‐Chao Song
British Journal of Clinical Pharmacology.2022; 88(3): 1279. CrossRef
A Simple Risk Scoring System for Predicting the Occurrence of Aspiration Pneumonia After Gastric Endoscopic Submucosal Dissection
Kyemyung Park, Na Young Kim, Ki Jun Kim, Chaerim Oh, Dongwoo Chae, So Yeon Kim
Anesthesia & Analgesia.2022; 134(1): 114. CrossRef
Virtual reality distraction during upper gastrointestinal endoscopy: a randomized controlled trial
Natapak Boonreunya, Ekapong Nopawong, Karn Yongsiriwit, Sakkarin Chirapongsathorn
Journal of Gastroenterology and Hepatology.2022; 37(5): 855. CrossRef
Endoscopist-Driven Sedation Practices in South Korea: Re-evaluation Considering the Nationwide Survey in 2019
Seon-Young Park, Jun Kyu Lee, Chang-Hwan Park, Byung-Wook Kim, Chang Kyun Lee, Hong Jun Park, Byung Ik Jang, Dong Uk Kim, Jin Myung Park, Jae Min Lee, Young Sin Cho, Hyung Ku Chon, Seung Young Seo, Woo Hyun Paik
Gut and Liver.2022; 16(6): 899. CrossRef
Abstract No. : ABS2330 : Comparison of three different sedative regimens for gastrointestinal endoscopic procedures
Parameshwaran Mahesh
Indian Journal of Anaesthesia.2022; 66(Suppl 1): S64. CrossRef
Prospective audit of the safety of endoscopist‐directed nurse‐administered propofol sedation in an Australian referral hospital
Montri Gururatsakul, Richard Lee, Sureshkumar Kallippatti Ponnuswamy, Rajit Gilhotra, Cathal McGowan, Debra Whittaker, John Ombiga, Peter Boyd
Journal of Gastroenterology and Hepatology.2021; 36(2): 490. CrossRef
Remimazolam tosilate in upper gastrointestinal endoscopy: A multicenter, randomized, non‐inferiority, phase III trial
Shao‐Hui Chen, Tang‐Mi Yuan, Jiao Zhang, Hua Bai, Ming Tian, Chu‐Xiong Pan, Hong‐Guang Bao, Xiao‐Ju Jin, Fu‐Hai Ji, Tai‐Di Zhong, Qiang Wang, Jian‐Rui Lv, Sheng Wang, Yu‐Juan Li, Yong‐Hao Yu, Ai‐Lin Luo, Xiang‐Kui Li, Su Min, Lin Li, Xiao‐Hua Zou, Yu‐Guan
Journal of Gastroenterology and Hepatology.2021; 36(2): 474. CrossRef
Airway Management for Initial PEG Insertion in the Pediatric Endoscopy Unit: A Retrospective Evaluation of 168 Patients
Jacquelin Peck, Anh Thy H. Nguyen, Aditi Dey, Ernest K. Amankwah, Mohamed Rehman, Michael Wilsey
Pediatric Gastroenterology, Hepatology & Nutrition.2021; 24(1): 100. CrossRef
Clinical efficacy of high-flow nasal oxygen in patients undergoing ERCP under sedation
Boram Cha, Man-Jong Lee, Jin-Seok Park, Seok Jeong, Don Haeng Lee, Tae Gyu Park
Scientific Reports.2021;[Epub] CrossRef
Management of Non-Variceal Upper GI Bleeding in the Geriatric Population: An Update
Eugene Stolow, Chris Moreau, Hari Sayana, Sandeep Patel
Current Gastroenterology Reports.2021;[Epub] CrossRef
Pain Intensity at Injection Site during Esophagogastroduodenoscopy Using Long- and Medium-Chain versus Long-Chain Triglyceride Propofol: A Randomized Controlled Double-Blind Study
Joon Seop Lee, Eun Soo Kim, Kwang Bum Cho, Kyung Sik Park, Yoo Jin Lee, Ju Yup Lee
Gut and Liver.2021; 15(4): 562. CrossRef
Risk Factors for Prolonged Hospital Stay after Endoscopy
Toshihiro Nishizawa, Shuntaro Yoshida, Osamu Toyoshima, Tatsuya Matsuno, Masataka Irokawa, Toru Arano, Hirotoshi Ebinuma, Hidekazu Suzuki, Takanori Kanai, Kazuhiko Koike
Clinical Endoscopy.2021; 54(6): 851. CrossRef
Endoscopic Ultrasound
Shelini Sooklal, Prabhleen Chahal
Surgical Clinics of North America.2020; 100(6): 1133. CrossRef
Comparison of Fentanyl versus Meperidine in Combination with Midazolam for Sedative Colonoscopy in Korea
Gwan Woo Hong, Jun Kyu Lee, Jung Hyeon Lee, Ji Hun Bong, Sung Hun Choi, Hyeki Cho, Ji Hyung Nam, Dong Kee Jang, Hyoun Woo Kang, Jae Hak Kim, Yun Jeong Lim, Moon Soo Koh, Jin Ho Lee
Clinical Endoscopy.2020; 53(5): 562. CrossRef
Continuous infusion versus intermittent bolus injection of propofol during endoscopic retrograde cholangiopancreatography
Jae Gon Lee, Kyo-Sang Yoo, Young Jae Byun
The Korean Journal of Internal Medicine.2020; 35(6): 1338. CrossRef
Low‐dose midazolam and propofol use for conscious sedation during diagnostic endoscopy
Joo Hyung Kim, Dae Hyun Kim, Jin Hong Kim
The Kaohsiung Journal of Medical Sciences.2019; 35(3): 160. CrossRef
The Use of Propofol for Continuous Deep Sedation at the End of Life: A Definitive Guide
John Bodnar
Journal of Pain & Palliative Care Pharmacotherapy.2019; 33(3-4): 63. CrossRef
Adverse events of conscious sedation using midazolam for gastrointestinal endoscopy
Jeeyoung Jun, Jong In Han, Ae Lee Choi, Youn Jin Kim, Jong Wha Lee, Dong Yeon Kim, Minjin Lee
Anesthesia and Pain Medicine.2019; 14(4): 401. CrossRef
Influence of midazolam-related genetic polymorphism on conscious sedation during upper gastrointestinal endoscopy in a Korean population
Jae Yong Park, Beom Jin Kim, Sang Wook Lee, Hyun Kang, Jeong Wook Kim, In-Jin Jang, Jae Gyu Kim
Scientific Reports.2019;[Epub] CrossRef
Using Etomidate and Midazolam for Screening Colonoscopies Results in More Stable Hemodynamic Responses in Patients of All Ages
Jung Min Lee, Geeho Min, Bora Keum, Jae Min Lee, Seung Han Kim, Hyuk Soon Choi, Eun Sun Kim, Yeon Seok Seo, Yoon Tae Jeen, Hoon Jai Chun, Hong Sik Lee, Soon Ho Um, Chang Duck Kim
Gut and Liver.2019; 13(6): 649. CrossRef
Effect of the midazolam added with propofol‐based sedation in esophagogastroduodenoscopy: A randomized trial
Eun Hye Kim, Jun Chul Park, Sung Kwan Shin, Yong Chan Lee, Sang Kil Lee
Journal of Gastroenterology and Hepatology.2018; 33(4): 894. CrossRef
Propofol for gastrointestinal endoscopy
Toshihiro Nishizawa, Hidekazu Suzuki
United European Gastroenterology Journal.2018; 6(6): 801. CrossRef
Pethidine dose and female sex as risk factors for nausea after esophagogastroduodenoscopy
Toshihiro Nishizawa, Hidekazu Suzuki, Masahide Arita, Yosuke Kataoka, Kazushi Fukagawa, Daisuke Ohki, Keisuke Hata, Toshio Uraoka, Takanori Kanai, Naohisa Yahagi, Osamu Toyoshima
Journal of Clinical Biochemistry and Nutrition.2018; 63(3): 230. CrossRef
Meperidine for patients expected to have poor tolerance to esophagogastroduodenoscopy: A double‐blind, randomized, controlled study
Chih-Wei Tseng, Malcolm Koo, Kuo-Chih Tseng, Yu-Hsi Hsieh
United European Gastroenterology Journal.2018; 6(9): 1307. CrossRef
Effect of dexmedetomidine in the prophylactic endoscopic injection sclerotherapy for oesophageal varices: a study protocol for prospective interventional study
Hiroki Nishikawa, Yoshinori Iwata, Akio Ishii, Hirayuki Enomoto, Yukihisa Yuri, Noriko Ishii, Yuho Miyamoto, Kunihiro Hasegawa, Chikage Nakano, Ryo Takata, Takashi Nishimura, Kazunori Yoh, Nobuhiro Aizawa, Yoshiyuki Sakai, Naoto Ikeda, Tomoyuki Takashima,
BMJ Open Gastroenterology.2017; 4(1): e000149. CrossRef
Italian Society of Digestive Endoscopy (SIED) position paper on the non-anaesthesiologist administration of propofol for gastrointestinal endoscopy
Rita Conigliaro, Lorella Fanti, Mauro Manno, Piero Brosolo
Digestive and Liver Disease.2017; 49(11): 1185. CrossRef
Sedation-related Adverse Events Associated with a Diagnostic Upper Endoscopy: A Single Center-observational Study
Jihyun Lee, Ki-Nam Shim, Kang Hoon Lee, Ko Eun Lee, Ji Young Chang, Chung Hyun Tae, Chang Mo Moon, Seong-Eun Kim, Hye-Kyung Jung, Sung-Ae Jung
The Korean Journal of Helicobacter and Upper Gastrointestinal Research.2017; 17(4): 185. CrossRef
A Response Surface Model Exploration of Dosing Strategies in Gastrointestinal Endoscopies Using Midazolam and Opioids
Jing-Yang Liou, Chien-Kun Ting, Ming-Chih Hou, Mei-Yung Tsou
Medicine.2016; 95(23): e3520. CrossRef
Sedacija virškinimo trakto endoskopinių procedūrų metu
Rasa Kučinskaitė, Aurika Karbonskienė
Sveikatos mokslai.2016; 26(4): 74. CrossRef
Dexmedetomidine versus midazolam for sedation during endoscopy: A meta-analysis
FAN ZHANG, HAO-RUI SUN, ZE-BING ZHENG, REN LIAO, JIN LIU
Experimental and Therapeutic Medicine.2016; 11(6): 2519. CrossRef
The median effective concentration (EC50) of propofol with different doses of fentanyl during colonoscopy in elderly patients
Shiyang Li, Fang Yu, Huichen Zhu, Yuting Yang, Liqun Yang, Jianfeng Lian
BMC Anesthesiology.2015;[Epub] CrossRef
Safety of Sedated Therapeutic Endoscopic Retrograde Cholangiopancreatography in Patients Older than 70 Years Old
Su Jung Baik, Sun Young Yi, Hye-Kyung Jung, Seong-Eun Kim
The Ewha Medical Journal.2014; 37(2): 92. CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format: